Laurent Villeneuve

TL;DR: A new, easy to use clinicopathological classification of pituitary endocrine tumours has demonstrated its prognostic worth by strongly predicting the probability of post-operative complete remission or tumour progression and so could help clinicians choose the best post-operation therapy.

TL;DR: From the findings, PIPAC has been shown to be feasible and safe and can be considered as a treatment option for refractory, isolated peritoneal metastasis of various origins, however, its use in further indications needs to be validated by prospective studies.

TL;DR: GASTRICHIP as discussed by the authors is a prospective, open, randomized multicenter phase III clinical study with two arms that aims to evaluate the effects of hyperthermic intraperitoneal chemotherapy with oxaliplatin on patients with gastric cancer involving the serosa and/or lymph node involvement and positive cytology at peritoneal washing.

TL;DR: This multiparameter investigation aimed to identify markers for recurrence and progression in prolactin tumors by retrospectively studying clinical data, tumor characteristics, clinical outcome, and the expression of nine genes by quantitative RT-PCR.

TL;DR: To review the 25‐year experience with hyperthermic intra‐peritoneal chemotherapy (HIPEC), the authors suggest that conventional chemotherapy should be considered as a best method to treat central giant cell granuloma.